Physician profile
Daniel J Holdman
NPI 1972768919
$5,118.00
in general payments reported to CMS, 2019-2025
33 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $588 · 2021: $1,213 · 2022: $928 · 2023: $798 · 2024: $449 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,643.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $491.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $457.59 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $389.08 | 2021-2023 | |
| Amgen INC. | $364.78 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $329.58 | 2019-2022 | |
| Pfizer INC. | $253.27 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.16 | 2019-2024 | Jardiance |
| Abbott Laboratories | $216.71 | 2021-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $110.47 | 2019-2021 | |
| Astellas Pharma US INC | $79.77 | 2021-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.54 | 2022-2024 | Xifaxan, Trulance |
| Allergan, INC. | $53.25 | 2019-2021 | |
| Biogen, INC. | $41.16 | 2021-2022 | |
| Glaxosmithkline, LLC. | $40.69 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $36.75 | 2020-2023 | |
| Organon LLC | $36.24 | 2021-2023 | Nexplanon |
| Dexcom, INC. | $35.34 | 2023-2024 | Dexcom G6 Transmitter |
| Corium, LLC | $32.25 | 2023 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $28.39 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.79 | 2023 | Rexulti |
| Coloplast Corp | $16.79 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $15.16 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.07 | 2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $15.02 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.88 | 2020 | |
| Amarin Pharma, INC. | $14.85 | 2022 | |
| Sanofi Pasteur INC. | $13.90 | 2019 | |
| Zyla Life Sciences, INC. | $13.21 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.54 | 2019 | |
| Nestle Healthcare Nutrition INC. | $11.40 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.07 | 2021 | |
| Hologic Sales and Service, LLC | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Holdman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.